Literature DB >> 30371536

Mucosal-associated Lymphoid Tissue (MALT) Lymphoma in Association With Pediatric Primary Sjogren Syndrome: 2 Cases and Review.

Melissa S Tesher1, Ysabella Esteban1, Tara O Henderson1, Gabriela Villanueva1, Karen B Onel2.   

Abstract

Mucosal-associated lymphoid tissue (MALT) lymphoma is rare in the pediatric population, but primary Sjogren syndrome is a well-established risk factor for this malignancy. This report describes 2 cases of MALT lymphoma in children with Sjogren syndrome. A 15-year-old girl developed MALT lymphoma of the parotid gland as the presenting symptom of Sjogren syndrome. In the second case, a 15-year-old boy with known Sjogren syndrome presenting mainly with arthritis was diagnosed with MALT lymphoma, also of the parotid gland. With early diagnosis and treatment, outcomes in pediatric MALT lymphoma are generally encouraging. Pediatric oncology specialists should be aware of the association of MALT lymphoma with Sjogren syndrome and have a high index of suspicion for this malignant complication.

Entities:  

Mesh:

Year:  2019        PMID: 30371536     DOI: 10.1097/MPH.0000000000001321

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

Review 1.  Astragalus polysaccharide: a review of its immunomodulatory effect.

Authors:  Chun-Xiao Li; Ying Liu; Yu-Zhen Zhang; Jing-Chun Li; Jiang Lai
Journal:  Arch Pharm Res       Date:  2022-06-17       Impact factor: 4.946

Review 2.  Unique Aspects of Pediatric Sjögren Disease.

Authors:  Rachel L Randell; Scott M Lieberman
Journal:  Rheum Dis Clin North Am       Date:  2021-08-27       Impact factor: 2.670

3.  Treatment strategies for Sjögren's syndrome with childhood onset: a systematic review of the literature.

Authors:  Georgia Doolan; Nor Mohd Faizal; Charlene Foley; Muthana Al-Obaidi; Elizabeth C Jury; Elizabeth Price; Athimalaipet V Ramanan; Scott M Lieberman; Coziana Ciurtin
Journal:  Rheumatology (Oxford)       Date:  2022-03-02       Impact factor: 7.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.